RKDA Arcadia Biosciences Inc

At the annual meeting of stockholders of Arcadia Biosciences, Inc. (the “Company”) held on June 3, 2019 (the “Annual Meeting”), stockholders holding and entitled to vote 3,965,647 shares of common stock of the Company, or approximately 83.01% of the total outstanding shares of common stock on the record date for the Annual Meeting, were present in person or by proxy. At the Annual Meeting, the stockholders voted on the following three proposals, each of which is described in detail in the definitive proxy statement filed with the Securities and Exchange Commission on April 18, 2019.

The final results for each of the matters considered at the Annual Meeting were as follows:

PROPOSAL I: Election of Directors

Each of the director nominees was elected to serve as a Class I director until the Company’s annual meeting of stockholders in 2022, or until his successor is duly elected and qualified, or his earlier resignation, death, or removal. Due to plurality election, votes could only be cast in favor of or withheld from the nominees and thus votes against were not applicable. The results of the election were as follows:

PROPOSAL II: Amendment to the 2015 Omnibus Incentive Plan (the “2015 Plan”)

The amendments to the Company’s 2015 Plan to (i) increase the number of shares of common stock that may be issued under the 2015 Plan by 120,000 shares, (ii) eliminate the fixed share cap included in the evergreen provision and (iii) make certain other changes to the 2015 Plan as described in the Proxy Statement were approved. The results of the approval were as follows:

PROPOSAL III: Ratification of Selection of Independent Registered Public Accountants

The appointment of Deloitte & Touche LLP as the Company’s independent registered public accountants for the year ending December 31, 2019, was ratified by the affirmative votes of the stockholders. There were no broker non-votes on this proposal. The results of the ratification were as follows: